These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 38594880)
1. A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL). Nogami N; Kubo T; Bessho A; Sakugawa M; Ikeo S; Yokoyama T; Seki N; Ochiai R; Fujimoto N; Murakami S; Kaira K; Harada T; Kishino D; Takiguchi Y; Shimokawa T; Kiura K; Yamashita N; Okamoto H Jpn J Clin Oncol; 2024 Jul; 54(7):805-812. PubMed ID: 38594880 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966 [TBL] [Abstract][Full Text] [Related]
3. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial. Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M; Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414 [TBL] [Abstract][Full Text] [Related]
4. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301. Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722 [TBL] [Abstract][Full Text] [Related]
5. A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer. Okuma Y; Hosomi Y; Takahashi S; Nakahara Y; Watanabe K; Nagamata M; Takagi Y; Mikura S Cancer Chemother Pharmacol; 2016 Aug; 78(2):383-8. PubMed ID: 27339149 [TBL] [Abstract][Full Text] [Related]
6. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189 [TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion. Tamiya M; Tamiya A; Suzuki H; Taniguchi Y; Katayama K; Minomo S; Nakao K; Takeuchi N; Matsuda Y; Naito Y; Shiroyama T; Okamoto N; Okishio K; Kumagai T; Atagi S; Imamura F; Hirashima T Invest New Drugs; 2021 Aug; 39(4):1106-1112. PubMed ID: 33544282 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Satouchi M; Okamoto I; Sakai H; Yamamoto N; Ichinose Y; Ohmatsu H; Nogami N; Takeda K; Mitsudomi T; Kasahara K; Negoro S Lung Cancer; 2013 Jul; 81(1):97-101. PubMed ID: 23545279 [TBL] [Abstract][Full Text] [Related]
9. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354 [TBL] [Abstract][Full Text] [Related]
10. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302). Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M; Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836 [TBL] [Abstract][Full Text] [Related]
12. Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma. Akiyama N; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Uto T; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Suda T Invest New Drugs; 2019 Jun; 37(3):531-537. PubMed ID: 30790149 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016). Miura S; Maemondo M; Iwashima A; Harada T; Sugawara S; Kobayashi K; Inoue A; Nakagawa T; Takiguchi Y; Watanabe H; Ishida T; Terada M; Kagamu H; Gemma A; Yoshizawa H Invest New Drugs; 2017 Apr; 35(2):227-234. PubMed ID: 28150074 [TBL] [Abstract][Full Text] [Related]
14. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer. Engel-Riedel W; Lowe J; Mattson P; Richard Trout J; Huhn RD; Gargano M; Patchen ML; Walsh R; Trinh MM; Dupuis M; Schneller F J Immunother Cancer; 2018 Feb; 6(1):16. PubMed ID: 29486797 [TBL] [Abstract][Full Text] [Related]
15. Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer. Yamasaki M; Murakami I; Nakano K; Doi M; Kitaguchi S; Kondo T; Sakurai J; Hattori N; Arita KI Anticancer Res; 2017 Feb; 37(2):923-928. PubMed ID: 28179353 [TBL] [Abstract][Full Text] [Related]
16. Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study. Shiroyama T; Tamiya M; Minami S; Takata S; Masuhiro K; Futami-Nishijima Y; Uenami T; Mori M; Koba T; Matsuki T; Takimoto T; Suzuki H; Okamoto N; Komuta K; Hirashima T; Kumanogoh A; Kijima T Cancer Chemother Pharmacol; 2017 Sep; 80(3):461-467. PubMed ID: 28688052 [TBL] [Abstract][Full Text] [Related]
17. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351 [TBL] [Abstract][Full Text] [Related]
18. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421 [TBL] [Abstract][Full Text] [Related]
19. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer. Fang Y; Wang L; Xia GH; Shi MQ Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858 [TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]